Trial Profile
An Open-label Expanded Access Trial of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease Who Require Enzyme Replacement Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease
- Focus Adverse reactions; Expanded access
- Sponsors Pfizer; Protalix Biotherapeutics
- 04 Dec 2018 Results assessing tolerability of taliglucerase alfa in patients with Gaucher's disease, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 20 Jun 2014 New trial record